Advanced Filters
noise
Found 2,256 clinical trials
R Rocío Grajales Álvarez, MD.

Digital Health Intervention to Improve Health Care and Outcomes for Breast Cancer Patients

Background: Nearly 30,000 Mexican women develop breast cancer annually. These patients frequently present multiple unmet supportive care needs. In high-income settings, incorporating electronic patient-reported outcomes (ePROs) into cancer care has demonstrated potential for increasing patient-centred care and reducing unmet needs. No such ePRO interventions have been implemented in Mexico. The …

20 - 75 years of age Female Phase 2
D Didier MAYEUR, Dr

Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL

This study recommends the use of OnLife dietary supplement, which will be followed by a few day before the initiation of PACLITAXEL, for the prevention of PACLITAXEL induced neuropathy. OnLife will be continued one month after stopping chemotherapy. This would limit the number of PACLITAXEL dose reductions and premature interruptions …

18 years of age Female Phase 2
Y Yue Chai, Dr.

SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer

To evaluate the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen in HER2 low-expressing metastatic breast cancer

18 years of age Female Phase 2
N Nusayba Bagegni, M.D.

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant treatment selection. It is the hypothesis that this will improve clinical response for postmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer and identify those who may not require neoadjuvant chemotherapy, with a primary focus on outcomes …

18 years of age Female Phase 2
Q Qurat-ul-ain Khan, MS

Outpatient Versus Tele Rehabilitation Among Post-surgical Breast Cancer Survivors

This study is comparing two interventions to identify effective treatment for breast cancer patients.

30 - 60 years of age Female Phase N/A
N Nebojsa Ivanovic, Dr

Anti-Inflammatory Diet in BRC Patients on Aromatase Inhibitors

This project aims to decrease undesirable side effects and increase qulaity of life of aromatase inhibitors therapy in breast cancer survivors, by anti-inflammatory diet or supplementation.

45 - 70 years of age Female Phase N/A
X Xiaosong Chen

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

Investigators plan to conduct a single-arm clinical study of adebelimab, a novel PD-L1 inhibitor, in the neoadjuvant treatment of early or locally advanced high-risk ER+/HER2- breast cancer, to explore whether the addition of immune checkpoint inhibitors to traditional neoadjuvant chemotherapy can improve the pathologic complete response rate (pCR) of patients, …

18 - 65 years of age Female Phase 2
S Stephen Chia, MD

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Advanced hormone positive (HR+), HER2 negative breast cancer continues to pose a challenge when patients have progressed on CDK4/6 inhibitor and endocrine therapy leaving limited treatment options. Antibody-drug conjugates (ADCs) such as sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) have changed practice due to significant improvement in progression free survival …

18 years of age All Phase 2
J Jihui Hao, MD

A Clinical Study of HRS-6209 in Combination With Letrozole in Patients With Breast Cancer

This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with letrozole in breast cancer patients, and preliminarily observe its anti-tumor efficacy.

18 - 75 years of age Female Phase 1/2

A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors

The purpose of this research is to evaluate the effectiveness of a multidisciplinary pain management program for AIMSS in reducing pain, subjective cognitive complaints, psychological distress, and impaired functional status resulting in improved adherence to Aromatase Inhibitor medications compared to usual care. We want to identify predictors of improvement in …

18 years of age All Phase N/A

Simplify language using AI